US Market News
2月前
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRApril 20, 2026 1:58 AM
PR Newswire (US)
LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302746762.htmlSOURCE DJS Law Group LLP
Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
US Market News
2月前
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRApril 13, 2026 2:40 AM
PR Newswire (US)
LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302740073.htmlSOURCE DJS Law Group LLP
Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
US Market News
2月前
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRApril 6, 2026 4:14 AM
PR Newswire (US)
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025
DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302734449.htmlSOURCE DJS Law Group LLP
Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
US Market News
3月前
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRMarch 23, 2026 2:10 AM
PR Newswire (US)
LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302721721.htmlSOURCE DJS Law Group LLP
Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
US Market News
3月前
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRMarch 20, 2026 4:06 AM
PR Newswire (US)
LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302719512.htmlSOURCE DJS Law Group LLP
Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
US Market News
3月前
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRMarch 16, 2026 3:09 AM
PR Newswire (US)
LOS ANGELES, March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302714246.htmlSOURCE DJS Law Group LLP
Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
iHub News
4月前
Nektar gains after durable efficacy shown in atopic dermatitis studyFebruary 10, 2026 10:46 AM
IH Market News
Shares of Nektar Therapeutics (NASDAQ:NKTR) moved higher on Tuesday after the company released encouraging long-term maintenance results from its REZOLVE-AD trial of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The stock was up about 3% in morning trading.The clinical-stage biotech said patients receiving rezpegaldesleukin, a regulatory T-cell–targeting biologic, sustained strong clinical responses through week 52 under both monthly and quarterly dosing schedules.Trial data showed that 71% of patients on a 24 µg/kg monthly regimen and 83% on quarterly dosing maintained EASI-75 responses. For vIGA-AD 0/1 outcomes, 85% of monthly-dosed patients and 63% of those on quarterly dosing sustained their responses. The company also reported up to a fivefold increase in EASI-100 responses, signaling complete skin clearance in a subset of patients.REZOLVE-AD is a global Phase 2b study that enrolled 393 patients. After a 16-week induction phase, participants who achieved at least a 50% improvement in EASI scores were re-randomized to receive maintenance therapy either monthly or quarterly for a further 36 weeks.Nektar said the treatment’s safety profile remained consistent with earlier findings, with no new safety signals observed during the maintenance phase. Discontinuations due to adverse events were limited to 3.5% across all patients.“These data validate the novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator,” the company said, adding that the durability of responses supports moving into a pivotal Phase 3 program evaluating both dosing schedules.Nektar plans to submit a Biologics License Application for rezpegaldesleukin in 2029.Nektar Therapeutics stock price
Original: Nektar gains after durable efficacy shown in atopic dermatitis study
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
1hot toddy
4月前
SphinxElf1
7月前
Acme Investments
12月前
TrendTrade2016
12月前
glenn1919
12月前
Monksdream
2年前
メールアドレスで登録
